Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL283164 | 1.00 | CNR2 (0.78) | CNR2CNR1 | |
| SCHEMBL283165 | 1.00 | CNR2 (0.78) | CNR2CNR1 | |
| SCHEMBL283162 | 1.00 | CNR2 (0.78) | CNR2CNR1 | |
| SCHEMBL2817731 | 0.90 | CNR2 (0.82) | CNR2 | |
| SCHEMBL2817729 | 0.90 | CNR2 (0.82) | CNR2 | |
| SCHEMBL283426 | 0.88 | CNR2 (1.00) | CNR2 | |
| SCHEMBL25631684 | 0.88 | CNR2 (1.00) | CNR2 | |
| SCHEMBL283427 | 0.88 | CNR2 (1.00) | CNR2 | |
| SCHEMBL283025 | 0.86 | CNR2 (0.89) | CNR2 | |
| SCHEMBL283026 | 0.86 | CNR2 (0.89) | CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2428507-B1 | Cannabinoid receptor ligands | ABBVIE BAHAMAS LTD (BS) | 2015-10-21 | — | — | EP | disclosed |
| EP-2896615-A1 | Cannabinoid receptor ligands | AbbVie Bahamas Limited (BS) | 2015-07-22 | — | — | EP | disclosed |
| US-8859596-B2 | Compounds as cannabinoid receptor ligands | ABBVIE INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-8188135-B2 | Compounds as cannabinoid receptor ligands | ABBOTT LABORATORIES (US) | 2012-05-29 | — | — | US | disclosed |
| EP-2428507-A2 | Cannabinoid receptor ligands | Abbott Laboratories (US) | 2012-03-14 | — | — | EP | disclosed |
| US-20100069348-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100069349-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069348-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, NPY1R | CNR2 2/4885CNR1 1/4885 |
| US-20100069349-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, NPY1R | CNR2 2/4885CNR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.